LAVA Therapeutics Announces Appointment of Christy J. Oliger to its Board of Directors
UTRECHT, The Netherlands and PHILADELPHIA, March 09, 2023 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), a clinical-stage immuno-oncology company...
Cancer
Ocean Biomedical (NASDAQ: OCEA) Shares Detailed Research Data on Anti-Tumor Pathway Discoveries and Their Potential for Treatment of Non-Small Cell Lung Cancer, Metastatic Melanoma, and Glioblastoma by Scientific Co-founder
Illustration 1: Effect of anti-CHI3L1 on Primary Lung Cancer Illustration 2: Effect of bi-specific antibody on Glioblastoma tumorsProvidence, RI, March...
EDAP to Announce Fourth Quarter and Full-Year 2022 Financial Results on Thursday, March 30th
LYON, France, March 9, 2023 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based therapies,...
Chiara Family Foundation Winter Classic hockey game raises $300,000 in support of the MUHC Foundation
Chiara Family Foundation Winter Classic hockey game raises $300,000 in support of the MUHC Foundation The game between Montreal Canadiens...
Vaccinex Reports that KEYNOTE B-84 has Reached Targeted Enrollment for Pre-planned Interim Analysis
Interim analysis will be performed when the last of these patients has completed a tumor assessment scan approximately 9 weeks...
Novel Target-Specific Nanoparticles for Diagnosis and Treatment of Pancreatic Cancer
By Dr. Jill Smith Pancreatic cancer is well known as one of the deadliest cancers, with a paltry 11% survival...
Molecure announces first patient dosed in Phase I trial with novel, first-in-class dual arginase inhibitor OATD-02 for the treatment of cancer
Marcin Szumowski Chief Executive Officer Samson Fung Chief Medical Officer OATD-02 First-in-class dual arginase inhibitorMolecure announces first patient dosed in...
AIM ImmunoTech Announces Publication of New Analysis of the Mechanism of Action of Ampligen as a Potential Prophylactic Therapy Against Ebola Virus Disease
OCALA, Fla., March 08, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), an immuno-pharma...
Data on Potential Biomarker for Qualigen Therapeutics’ Lead Program QN-302 Published in Peer-Reviewed Journal Molecules
S100P Gene Expression May Be Marker of Anti-Tumor Activity in Pancreatic Cancer In Vivo Models CARLSBAD, Calif., March 08, 2023...
MaxCyte Establishes New Scientific Advisory Board Comprised of Globally Recognized Experts in Cell Engineering Enabling Technology
MaxCyte’s Scientific Advisory Board will provide guidance to shape the technical direction of the company’s innovation initiatives focused on the...
Replimune to Present at Two Upcoming Investor Conferences
WOBURN, Mass., March 08, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the...
OPKO Health’s ModeX Therapeutics Enters into Exclusive Worldwide License and Collaboration Agreement with Merck to Develop Epstein-Barr Virus Vaccine Candidate
MDX-2201 leverages ModeX’s innovative biologics platform to target multiple Epstein-Barr virus (EBV) proteinsEBV is the leading cause of infectious mononucleosis...
Panbela to Host Fourth Quarter and Year End 2022 Earnings Conference Call on March 16, 2023
MINNEAPOLIS, March 08, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for...
Protara Therapeutics Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
- Data from Phase 1a Portion of ADVANCED-1 Trial of TARA-002 for the Treatment of Non-Muscle Invasive Bladder Cancer Expected...
Achieve Life Sciences Announces Last Subject Last Visit Completed in Phase 2 ORCA-V1 Trial of Cytisinicline for e-Cigarette Cessation
Topline Data Expected in 2Q 2023SEATTLE, Wash. and VANCOUVER, British Columbia, March 08, 2023 (GLOBE NEWSWIRE) -- Achieve Life Sciences,...
MiNK Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results
NEW YORK, March 07, 2023 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery,...
Inovalon Announces Converged Provider Enablement
A SaaS Solution that Aligns Disparate Quality, Risk, and Custom Value-Based Initiatives Across Multiple Provider Points of CareBOWIE, Md., March...
Elevar Therapeutics Debuts New Corporate Headquarters in Fort Lee, New Jersey
Presence in pharmaceutical industry hotbed allows Elevar to recruit top talent as it continues toward a commercial launch of cancer...
F-star Therapeutics Announces CFIUS Clearance for Proposed Acquisition by invoX Pharma
Parties expect the merger to be completed promptly following the successful completion of the ongoing Tender OfferCAMBRIDGE, United Kingdom and...
SELLAS Announces Publication of Positive GPS Clinical Data in Ovarian Cancer in Peer Reviewed Journal
Safety and Immunogenicity Examined in Phase 1 Trial of GPS plus Anti–PD-1 Nivolumab in Patients with WT1-Expressing Relapsed Ovarian Cancer...